Trial reportTranslational stroke research2020
Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial.
Trial report in Translational stroke research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00875654 (Cell Therapy by Intravenous Injection of Mesenchymal Stem Cells After Stroke), which is not on this map. Cited by 127 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cell Therapy by Intravenous Injection of Mesenchymal Stem Cells After Stroke
Who cites it
127 citing papers in PubMed, 12 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Targeting Neuroinflammation in Adult Ischemic Stroke: Direct Immunotherapy, Regenerative Cell-Based Strategies, and Translational Challenges-A Systematic Review with Exploratory Meta-analysis.Molecular neurobiology · 2026Pooled it
- Preclinical studies of conditioned medium of hypoxic-preconditioned mesenchymal stem cell/hypMSC-CM for ischemic stroke: A systematic review.Open veterinary journal · 2026Pooled it
- Efficacy and safety of stem cell therapy for acute and subacute ischemic stroke: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- The efficacy and safety of stem cell therapy for ischemic stroke: a systematic review and network meta-analysis study.BMC neurology · 2025Pooled it
- Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis.Stem cells translational medicine · 2024Pooled it
- Efficacy and safety of mesenchymal stem cells in patients with acute ischemic stroke: a meta-analysis.BMC neurology · 2024Pooled it
- Neuroprotective Effects of Conditioned Medium of Mesenchymal Stem Cells (MSC-CM) as a Therapy for Ischemic Stroke Recovery: A Systematic Review.Neurochemical research · 2023Pooled it
- Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke patients, a systematic review and meta-analysis.Frontiers in stroke · 2023Pooled it
- Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke - A Systematic Review and Meta-Analysis.Frontiers in neurology · 2022Pooled it
- Stem cell therapy for ischemic stroke: neuroimaging approaches and evidence from a systematic review.Frontiers in neurologyPooled it
- Stem Cell-Based Therapies via Different Administration Route for Stroke: A Meta-analysis of Comparative Studies.Cell transplantationPooled it
- Efficacy of cell transplantation for ischemic stroke: A meta-analysis of randomized controlled trials.Cell transplantationPooled it
- Safety and efficacy of allogeneic umbilical cord blood cells and erythropoietin combination therapy in patients with subacute stroke.Stem cell research & therapy · 2025Trial
- Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Trial
- The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial.BMC neurology · 2022Trial
- Trial
- Cell Therapy as Metabolic Rescue after Ischemic Stroke: Rewiring Bioenergetics, Redox Homeostasis, and Neurovascular Repair.Stem cell reviews and reports · 2026Review
- Advances in the clinical application of mesenchymal stem cells for neurological disorders.Stem cell research & therapy · 2026Review
- Bone marrow-derived mesenchymal stem cells for ischemic stroke: mechanisms, delivery strategies, clinical evidence, and translational challenges.Stem cell research & therapy · 2026Review
- Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton's Jelly Mesenchymal Stem Cells in the Orchestrum.Brain sciences · 2026Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
While preclinical stroke studies have shown that mesenchymal stem cells (MSCs) promote recovery, few randomized controlled trials (RCT) have assessed cell therapy in humans. In this RCT, we assessed the safety, feasibility, and efficacy of intravenous autologous bone marrow-derived MSCs in subacute stroke. ISIS-HERMES was a single-center, open-label RCT, with a 2-year follow-up. We enrolled patients aged 18-70 years less than 2 weeks following moderate-severe ischemic carotid stroke. Patients were randomized 2:1 to receive intravenous MSCs or not. Primary outcomes assessed feasibility and safety. Secondary outcomes assessed global and motor recovery. Passive wrist movement functional MRI (fMRI) activity in primary motor cortex (MI) was employed as a motor recovery biomarker. We compared "treated" and "control" groups using as-treated analyses. Of 31 enrolled patients, 16 patients received MSCs. Treatment feasibility was 80%, and there were 10 and 16 adverse events in treated patients, and 12 and 24 in controls at 6-month and 2-year follow-up, respectively. Using mixed modeling analyses, we observed no treatment effects on the Barthel Index, NIHSS, and modified-Rankin scores, but significant improvements in motor-NIHSS (p = 0.004), motor-Fugl-Meyer scores (p = 0.028), and task-related fMRI activity in MI-4a (p = 0.031) and MI-4p (p = 0.002). Intravenous autologous MSC treatment following stroke was safe and feasible. Motor performance and task-related MI activity results suggest that MSCs improve motor recovery through sensorimotor neuroplasticity. ClinicalTrials.gov Identifier NCT00875654.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.